Finance

Lists
O15:FRA
Insilico Medicine Cayman TopCo
€5.15
-2.83%
(-0.15) 1D
Sep 7, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for O15...
Open
€5.30
High
€5.30
Low
€5.15
Mkt. cap
27.76B
Avg. vol.
1.03K
Volume
280.00
52-wk high
€9.00
52-wk low
€3.58
No. of employees
333
Open
€5.30
High
€5.30
Low
€5.15
Mkt. cap
27.76B
Avg. vol.
1.03K
Volume
280.00
52-wk high
€9.00
52-wk low
€3.58
No. of employees
333
Profile
Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery. Wikipedia
About Insilico Medicine Cayman TopCo
CEOFeng Ren | Alex Zhavoronkov
Employees333
Founded2014
Headquarters-
SectorHealth care
Websiteinsilico.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
14.39M
14.39M
53.15M
53.15M
Cost of goods sold
2.98M
2.98M
5.17M
5.17M
Cost of revenue
2.98M
2.98M
5.17M
5.17M
Research and development expenses
22.90M
22.90M
24.66M
24.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.05M
7.05M
9.47M
9.47M
Operating expense
30.23M
30.23M
33.85M
33.85M
Total operating expenses
33.20M
33.20M
39.02M
39.02M
Operating income
-18.81M
-18.81M
14.14M
14.14M
Other non operating income
-149.82M
-149.82M
1.50K
1.50K
EBT including unusual items
-166.54M
-166.54M
17.91M
17.91M
EBT excluding unusual items
-167.61M
-167.61M
16.57M
16.57M
Income tax expense
9.50K
9.50K
139.50K
139.50K
Effective tax rate
-0.01%
-0.01%
0.78%
0.78%
Other operating expenses
-
-
-
-
Net income
-166.55M
-166.55M
17.77M
17.77M
Net profit margin
-1,157.28%
-1,157.28%
33.43%
33.43%
Earnings per share
-
-
-
-
Interest and investment income
1.29M
1.29M
3.89M
3.89M
Interest expense
-56.00K
-56.00K
-83.00K
-83.00K
Net interest expenses
1.24M
1.24M
3.81M
3.81M
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.08M
-18.08M
14.89M
14.89M
Gain or loss from assets sale
63.50K
63.50K
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps